Dermavant Sciences, Inc.

Founded in 2016 and based in California, US, Dermavant Sciences, Inc. operates as a biotechnology company that develops therapies and therapeutics product candidates for immuno-dermatology conditions such as psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne. The company was a subsidiary of Roivant Sciences, a biopharmaceutical company. The company's CEO is Mr.

Todd Zavodnick. In June 2021, Dermavant Sciences, Inc. received its first venture funding from a group of investors that includes Marathon Asset Management, NovaQuest Capital Management, and other institutional investors in Boston. The company's product is composed of therapeutic product candidates that provide treatment for immuno-dermatology conditions such as psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and acne.

The company develops Tapinarof (DMVT-505), a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream that provides treatment for psoriasis and atopic dermatitis; Cerdulatinib (DMVT-502), a therapeutic solution for vitiligo and atopic dermatitis; Ocybutynin/Pilocarpine (DMVT-504), an oral combination of immediate-release muscarinic antagonist and delayed-release muscarinic agonist providing a solution for primary focal hyperhidrosis; DMVT-503, a product dedicate for acne vulgaris; and Lotamilast (DMVT-501), a selective topical PDE4 inhibitor for atopic dermatitis. The company's revenue is generated by the sales of its dermatological products to its target market around the US. The company plans to proceed to the approval of the commercialization of Tapinarof for the treatment of psoriasis in the United States.